Humanigen, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own11.96% Shs Outstand119.08M Perf Week-0.67%
Market Cap15.75M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float104.84M Perf Month1.13%
Income-108.70M PEG- EPS next Q-0.06 Inst Own6.10% Short Float / Ratio6.24% / 1.98 Perf Quarter40.76%
Sales3.30M P/S4.77 EPS this Y-66.90% Inst Trans-67.36% Short Interest6.54M Perf Half Y-23.73%
Book/sh-0.52 P/B- EPS next Y66.00% ROA-199.60% Target Price- Perf Year-95.79%
Cash/sh0.21 P/C0.64 EPS next 5Y12.50% ROE287.40% 52W Range0.09 - 3.39 Perf YTD11.67%
Dividend- P/FCF- EPS past 5Y21.90% ROI- 52W High-96.05% Beta-0.83
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low45.02% ATR0.01
Employees11 Current Ratio0.30 Sales Q/Q-80.00% Oper. Margin- RSI (14)40.70 Volatility5.56% 9.05%
OptionableYes Debt/Eq- EPS Q/Q79.20% Profit Margin- Rel Volume0.13 Prev Close0.14
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.31M Price0.13
Recom3.30 SMA20-8.20% SMA50-16.33% SMA200-67.13% Volume510,428 Change-0.96%
Jul-13-22Downgrade ROTH Capital Buy → Neutral $13 → $2
Jul-13-22Downgrade H.C. Wainwright Buy → Neutral
Jul-13-22Downgrade Cantor Fitzgerald Overweight → Neutral $30 → $2
Sep-10-21Downgrade Jefferies Buy → Hold $9
Sep-09-21Reiterated H.C. Wainwright Buy $36 → $28
Sep-09-21Downgrade JP Morgan Neutral → Underweight
Sep-09-21Downgrade Credit Suisse Outperform → Neutral
Jun-11-21Initiated Credit Suisse Outperform $28
May-07-21Initiated Oppenheimer Outperform $30
Feb-23-21Initiated JP Morgan Neutral $21
Show Previous Ratings
Nov-14-22 04:01PM
Nov-10-22 08:02AM
Oct-31-22 08:01AM
Sep-12-22 06:55AM
Sep-07-22 06:55AM
04:00PM Loading…
Aug-12-22 04:00PM
Jul-26-22 07:30AM
Jul-13-22 05:22PM
Jul-12-22 08:30PM
Jul-06-22 11:34PM
Jun-30-22 08:19AM
Jun-16-22 06:30AM
07:04AM Loading…
Jun-15-22 07:04AM
Jun-03-22 07:00AM
May-24-22 06:30AM
May-11-22 08:43PM
May-09-22 06:15AM
May-05-22 04:00PM
May-04-22 07:00AM
Apr-19-22 06:30AM
Apr-07-22 01:35PM
Mar-17-22 03:47PM
Feb-28-22 01:05PM
Feb-25-22 05:55AM
Feb-11-22 05:55AM
Feb-09-22 11:55PM
Feb-08-22 11:55PM
08:26AM Loading…
Feb-06-22 08:26AM
Jan-18-22 05:55AM
Jan-10-22 05:55AM
Jan-06-22 03:11PM
Jan-05-22 06:05AM
Jan-04-22 05:55AM
Jan-03-22 05:55AM
Dec-15-21 08:59AM
Dec-01-21 06:45PM
Nov-22-21 06:30AM
Nov-16-21 07:47AM
Nov-12-21 04:00PM
Nov-11-21 06:30AM
Nov-07-21 08:34AM
Nov-05-21 10:34AM
Nov-02-21 08:30AM
Oct-26-21 05:31PM
Oct-22-21 07:00AM
Oct-20-21 07:00AM
Oct-19-21 07:00AM
Oct-11-21 12:53PM
Oct-08-21 02:00AM
Oct-04-21 11:00PM
Oct-01-21 09:00AM
Sep-29-21 08:00AM
Sep-28-21 08:28AM
Sep-27-21 10:58AM
Sep-21-21 05:02PM
Sep-20-21 12:38AM
Sep-14-21 12:56PM
Sep-10-21 01:10PM
Sep-09-21 09:43PM
Aug-25-21 09:14AM
Aug-12-21 04:00PM
Aug-09-21 03:19AM
Aug-04-21 06:00AM
Aug-02-21 02:02PM
Jul-30-21 11:06AM
Jul-26-21 08:00AM
Jul-22-21 09:59AM
Jul-13-21 06:51PM
Jul-12-21 08:40AM
Jul-09-21 06:30AM
Jun-28-21 11:46AM
Jun-25-21 02:27AM
Jun-14-21 06:30AM
Jun-07-21 08:00AM
Jun-03-21 08:00AM
May-28-21 09:00AM
May-26-21 08:30AM
May-19-21 07:00AM
May-17-21 08:00AM
May-13-21 04:01PM
May-11-21 04:19AM
May-05-21 11:53AM
Apr-21-21 07:00AM
Apr-19-21 07:00AM
Apr-09-21 08:19AM
Apr-06-21 02:02PM
Mar-30-21 08:08PM
Mar-29-21 04:11PM
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chappell DaleChief Scientific OfficerMay 20Buy2.23545,4881,215,3478,675,081May 20 05:57 PM
Chappell DaleChief Scientific OfficerMay 19Buy2.19323,808707,8448,293,240May 20 05:57 PM
Chappell DaleChief Scientific OfficerMay 18Buy1.96173,700340,7998,066,575May 20 05:57 PM